Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks
EFG could be an elegant alternative to both IVIG and SPA-IA therapies for anti-NMDAR encephalitis during acute attacks. It has a better effect on reducing antibody titers than IVIG and is comparable to SPA-IA therapy, and no serious adverse events were observed during infusion.
Authors
- Yanxia Zhou (ORCID: https://orcid.org/0000-0003-0393-8136)
- Ying Jiang (ORCID: https://orcid.org/0000-0002-0040-4211)
- Min Li (ORCID: https://orcid.org/0000-0002-6006-604X)
- Jia Liu (ORCID: https://orcid.org/0000-0001-8413-6308)
- Xuemei Chen (ORCID: https://orcid.org/0000-0003-0798-8616)
- Zheng Dong (ORCID: https://orcid.org/0000-0002-1668-0843)
- Junyu Liu (ORCID: https://orcid.org/0000-0002-5199-7002)
- Xu Xiaofeng (ORCID: https://orcid.org/0000-0002-4090-902X)
- Lu Yang
- Fuhua Peng (ORCID: https://orcid.org/0000-0002-0191-0087)
- Yi Li (ORCID: https://orcid.org/0000-0002-5801-6000)
- Yee-Shin Lin
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Yulin University (CN)
- Guangdong 999 Brain Hospital (CN)
- Shenzhen Second People's Hospital (CN)
- Guhua Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Life Sciences
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.lfs.2025.123597
- Citations
- 4
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56